I027*
|
64
|
Female
|
E. coli
†
|
Fortum, ceftriaxone
|
UGIB
|
Non-survivor
|
I028‡
|
81
|
Female
|
Corynebacterium spp.
|
Ceftriaxone, fortum, clindamycin
|
T2D
|
Survivor
|
I029‡
|
74
|
Female
|
S. aureus
|
Fortum, ceftriaxone, tazocin
|
Asthma, emphysema, ARF
|
Survivor
|
I031*
|
48
|
Male
|
Enterococcus spp.
|
Fortum
|
Urinary tract infection
|
Survivor
|
I032*
|
54
|
Female
|
E. faecium
|
Fortum, tazocin
|
T2D, respiratory failure
|
Non-survivor
|
I033*
|
63
|
Female
|
E. coli
†
|
Tazocin, ceftriaxone, fortum
|
T2D, ovarian cancer
|
Survivor
|
I034*
|
43
|
Male
|
A. hydrophila
†
|
Tazocin
|
-
|
Survivor
|
Septicemic melioidosis (n = 8)
| | | | | | |
M031*
|
49
|
Male
|
B. pseudomallei
|
Fortum, bactrim, tazocin
|
T2D
|
Non-survivor
|
M032*
|
54
|
Male
|
B. pseudomallei
|
Fortum, doxycycline, sulperazone
|
T2D
|
Non-survivor
|
M033*
|
44
|
Male
|
B. pseudomallei
|
Fortum, sulperazone, bactrim, ciprofloxacin
|
T2D
|
Survivor
|
M034*
|
40
|
Female
|
B. pseudomallei
|
Fortum, bactrim, ceftazidime, ceftriaxone
|
T2D
|
Survivor
|
M035*
|
56
|
Male
|
B. pseudomallei
|
Ceftriaxone, ceftazidime, fortum
|
COPD, T2D
|
Non-survivor
|
M036*
|
41
|
Female
|
B. pseudomallei
|
Ceftriaxone, ceftazidime
|
T2D
|
Non-survivor
|
M037*
|
42
|
Female
|
B. pseudomallei
|
Bactrim, fortum, cloxacillin
|
T2D
|
Survivor
|
M038*
|
49
|
Female
|
B. pseudomallei
|
Ceftriaxone, fortum, ceftazidime, levofloxacin
|
-
|
Non-survivor
|